Although conventional and pegylated IFN-α have been first-line treatments for patients with chronic hepatitis B (CHB) (24, 25), the viral clearance rate of IFN-α treatments in CHB patients is rather low (26, 27). The gene discussed is IFNA1; the disease is chronic hepatitis B virus infection.